LON:RENX Renalytix (RENX) Share Forecast, Price & News GBX 87.50 0.00 (0.00%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range 85▼ 88.7550-Day Range 81▼ 95.2052-Week Range 44▼ 192.49Volume8,977 shsAverage Volume67,281 shsMarket Capitalization£82.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsInsider TradesHeadlinesProfileChartCompetitorsInsider TradesHeadlines About Renalytix (LON:RENX) StockRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.Read More Receive RENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address RENX Stock News HeadlinesMay 31, 2023 | uk.movies.yahoo.comIs the Renalytix share price a bargain or a falling knife?April 20, 2023 | marketwatch.comNew Published Real-World Evidence Shows KidneyIntelX(TM) UtilityJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.April 19, 2023 | finance.yahoo.comNew Published Real-World Evidence Shows KidneyIntelX™ UtilityApril 12, 2023 | finance.yahoo.comData Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical MeetingMarch 30, 2023 | finance.yahoo.comRenalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial ResultsMarch 21, 2023 | marketwatch.comRenalytix Shares Fall on Delay to FDA Marketing Authorization Decision on KidneyIntelXFebruary 9, 2023 | finance.yahoo.comRenalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceJune 7, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...February 8, 2023 | finance.yahoo.comRenalytix announces a c.$20.3 million private placementJanuary 26, 2023 | marketwatch.comRenalytix Shares Rise on $10 Mln Grant Award to Advance Chronic Kidney Disease TreatmentJanuary 26, 2023 | finance.yahoo.comRenalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United StatesJanuary 9, 2023 | finance.yahoo.comRenalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systemsDecember 1, 2022 | finance.yahoo.comPrimary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and OutcomesNovember 30, 2022 | finanznachrichten.deRenalytix AI, Inc.: Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023November 30, 2022 | msn.comWhat’s going on with the Renalytix share price?October 31, 2022 | finanznachrichten.deRenalytix plc: Renalytix Reports Full Year Fiscal 2022 ResultsOctober 24, 2022 | finance.yahoo.comRenalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31September 20, 2022 | finance.yahoo.comRenalytix Announces Change to Board of DirectorsAugust 17, 2022 | uk.finance.yahoo.comRenalytix Plc (RENX.L)August 8, 2022 | finance.yahoo.comData Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care PhysiciansJune 30, 2022 | fool.co.ukHere’s why the Renalytix share price is tankingJune 30, 2022 | finance.yahoo.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2022June 16, 2022 | uk.finance.yahoo.comThe Renalytix share price – where next?June 10, 2022 | finance.yahoo.com1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease PatientsJune 6, 2022 | finance.yahoo.comKidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient CohortJune 3, 2022 | stockhouse.comRenalytix Announces Two Data Presentations on KidneyIntelX(TM) at American Diabetes Association 82nd Scientific Sessions®See More Headlines RENX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:RENX CUSIPN/A CIKN/A Webwww.renalytixai.com Phone44 20 3139 2910FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-44,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.21% Return on Assets-48.55% Debt Debt-to-Equity Ratio58.94 Current Ratio1.96 Quick Ratio2.42 Sales & Book Value Annual Sales£3.80 million Price / Sales21.22 Cash FlowGBX 46.86 per share Price / Cash Flow1.84 Book ValueGBX 28 per share Price / Book3.07Miscellaneous Outstanding Shares93,780,000Free FloatN/AMarket Cap£80.65 million OptionableNot Optionable Beta1.97 Key ExecutivesMr. James R. McCullough M.B.A. (Age 55)CEO & Exec. Director Comp: $648kMr. Fergus Fleming (Age 56)CTO & Exec. Director Comp: $449kMr. Thomas H. McLain CPA (Age 64)M.B.A, Pres Mr. Oliver James Sterling IIIChief Financial OfficerMs. Andria Parks-HerreraVP of MarketingMs. Jean M. Casner (Age 64)Sr. VP & Chief HR Officer Mr. Baljit SinghHead of Clinical OperationsDr. Michael J. Donovan M.D. (Age 69)Ph.D., Chief Medical Officer Mr. Salim Hamir F.C.A.Company Sec.More ExecutivesKey CompetitorsCambridge CognitionLON:COGSourcebio InternationalLON:SBICreo Medical GroupLON:CREODiaceuticsLON:DXRXSareumLON:SARView All Competitors RENX Stock - Frequently Asked Questions How have RENX shares performed in 2023? Renalytix's stock was trading at GBX 72.50 at the beginning of the year. Since then, RENX shares have increased by 18.6% and is now trading at GBX 86. View the best growth stocks for 2023 here. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include United Microelectronics (UMC), Teva Pharmaceutical Industries (TEVA), SSP Group (SSPG), Sarepta Therapeutics (SRPT), Redrow (RDW), QUALCOMM (QCOM), Lloyds Banking Group (LLOY), Entain PLC (GVC.L) (GVC), Gamma Communications (GAMA) and eHealth (EHTH). What is Renalytix's stock symbol? Renalytix trades on the London Stock Exchange (LON) under the ticker symbol "RENX." How do I buy shares of Renalytix? Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Renalytix's stock price today? One share of RENX stock can currently be purchased for approximately GBX 86. How much money does Renalytix make? Renalytix (LON:RENX) has a market capitalization of £80.65 million and generates £3.80 million in revenue each year. The company earns £-44,940,000.00 in net income (profit) each year or GBX (0.64) on an earnings per share basis. How can I contact Renalytix? The official website for the company is www.renalytixai.com. The company can be reached via phone at 44 20 3139 2910. This page (LON:RENX) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.